{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:16Z","timestamp":1786650076115,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>Plasma cell leukemia (PCL) is a rare and an aggressive form of plasma cell dyscrasias. We report a 67-year-old male with PCL which developed while on imatinib mesylate (IM) therapy 38 months after diagnosis of chronic myeloid leukemia (CML). The patient has been treated successfully with bortezomib, melphalan and prednisolone. To our knowledge, only one case of PCL superimposed on Philadelphia positive CML has been reported in the literature and this was before the IM era.<\/jats:p>","DOI":"10.4103\/0973-1482.192762","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T09:03:38Z","timestamp":1531991018000},"page":"1431-1433","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate"],"prefix":"10.4103","volume":"14","author":[{"given":"Senem","family":"Maral","sequence":"first","affiliation":[{"name":"Department of Hematology, Ankara Ataturk Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sule Mine","family":"Bakanay","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yildirim Beyazit University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun Senturk","family":"Yikilmaz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yildirim Beyazit University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imdat","family":"Dilek","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yildirim Beyazit University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1634\/theoncologist.2009-0165","article-title":"Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months","volume":"14","author":"Michael","year":"2009","journal-title":"Oncologist"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1634\/theoncologist.10-6-457","article-title":"Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate","volume":"10","author":"Garipidou","year":"2005","journal-title":"Oncologist"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00277-008-0597-2","article-title":"Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia","volume":"88","author":"Galanopoulos","year":"2009","journal-title":"Ann Hematol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ajh.2830360317","article-title":"A case of plasma cell leukemia superimposed on Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia","volume":"36","author":"Sakai","year":"1991","journal-title":"Am J Hematol"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1046\/j.1365-2141.2003.04706.x","article-title":"Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents","volume":"123","author":"Pandiella","year":"2003","journal-title":"Br J Haematol"},{"key":"R6-20260109","first-page":"762","article-title":"Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia","volume":"88","author":"Steegmann","year":"2003","journal-title":"Haematologica"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.leukres.2010.01.012","article-title":"Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib","volume":"34","author":"Carulli","year":"2010","journal-title":"Leuk Res"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/annonc\/mdr480","article-title":"Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: A retrospective study from GIMEMA multiple myeloma working party","volume":"23","author":"D'Arena","year":"2012","journal-title":"Ann Oncol"},{"issue":"Suppl 11","key":"R9-20260109","first-page":"101a","article-title":"In vitro effects of PS-341 alone and in combination with STI571 in Bcr-Abl positive cell lines both sensitive and resistant to STI571","volume":"98","author":"Scappini","year":"2001","journal-title":"Blood"},{"key":"R10-20260109","first-page":"2297","article-title":"Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: Once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events","volume":"31","author":"Fukushima","year":"2011","journal-title":"Anticancer Res"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201814060-00047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:01:47Z","timestamp":1786647707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201814060-00047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.192762","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}